1.Analysis of Ecological Factors and Research Progress in Ecological Planting Mode of Pogostemon cablin
Yun-Zi BAO ; Lin-Yuan CHEN ; Kai-Ying QIU ; Yan-Mei NI ; Han-Qing DING ; Li-Ping WANG ; Zi-Qi LIU ; Ruo-Ting ZHAN ; Li-Kai CHEN
Journal of Guangzhou University of Traditional Chinese Medicine 2024;41(11):3084-3090
		                        		
		                        			
		                        			Pogostemon cablin is a famous southern medicine.As the important raw material for modern medicine and industry,Pogostemon cablin becomes required with a large marketing demand.However,due to the serious continuous cropping obstacles in the growth process of Pogostemon cablin,the aggravation of diseases of Pogostemon cablin and the degradation of its quality arose.This paper outlined the ecological factors such as climate factors,soil factors and topographic factors suitable for the growth of Pogostemon cablin,analyzed the continuous cropping obstacles and diseases arising in the cultivation,reviewed the current ecological planting mode of Pogostemon cablin such as crop rotation,intercropping,relay-cropping and under-forest planting,and also made a comprehensive evaluation of the economic benefits,ecological benefits and social benefits of the ecological planting mode of Pogostemon cablin,aiming to provide a theoretical basis and a reference for the promotion of the ecological planting mode of Pogostemon cablin.
		                        		
		                        		
		                        		
		                        	
2.Down-regulation of the Smad signaling by circZBTB46 via the Smad2-PDLIM5 axis to inhibit type I collagen expression.
Jing YU ; Wen-Zhao YAN ; Xin-Hua ZHANG ; Bin ZHENG ; Wen-Sen PAN ; Zhan YANG ; Hong ZHANG ; Zi-Yuan NIE ; Ying MA ; Yang BAI ; Long ZHANG ; Dan-Dan FENG ; Jin-Kun WEN
Journal of Geriatric Cardiology 2023;20(6):431-447
		                        		
		                        			BACKGROUND:
		                        			Abnormal type I collagen (COL1) expression is associated with the development of many cardiovascular diseases. The TGF-beta/Smad signaling pathway and circRNAs have been shown to regulate COL1 gene expression, but the underlying molecular mechanisms are still not fully understood.
		                        		
		                        			METHODS:
		                        			Gain- and loss-of-function experiments were prformed to study the effect of circZBTB46 on the expression of alpha 2 chain of type I collagen (COL1A2). Co-immunoprecipitation assay was performed to observe the interaction between two proteins. RNA immunoprecipitation assay and biotin pull-down assay were performed to observe the interaction of circZBTB46 with PDLIM5.
		                        		
		                        			RESULTS:
		                        			In this study, we investigated the role of circZBTB46 in regulating COL1A2 expression in human vascular smooth muscle cells (VSMCs). We found that circZBTB46 is expressed in VSMCs and that TGF-beta inhibits circZBTB46 formation by downregulating KLF4 expression through activation of the Smad signaling pathway. CircZBTB46 inhibits the expression of COL1A2 induced by TGF-beta. Mechanistically, circZBTB46 mediates the interaction between Smad2 and PDLIM5, resulting in the inhibition of Smad signaling and the subsequent downregulation of COL1A2 expression. Furthermore, we found that the expression of TGF-beta and COL1A2 is decreased, while circZBTB46 expression is increased in human abdominal aortic aneurysm tissues, indicating that circZBTB46-mediated regulation of TGF-beta/Smad signaling and COL1A2 synthesis in VSMCs plays a crucial role in vascular homeostasis and aneurysm development.
		                        		
		                        			CONCLUSIONS
		                        			CircZBTB46 was identified as a novel inhibitor of COL1 synthesis in VSMCs, highlighting the importance of circZBTB46 and PDLIM5 in regulating TGF-beta/Smad signaling and COL1A2 expression.
		                        		
		                        		
		                        		
		                        	
3.Similarities and differences of myocardial metabolic characteristics between HFpEF and HFrEF mice based on LC-MS/MS metabolomics.
Zhan Yi ZHANG ; Xue Ying FENG ; Zi Hao WANG ; Yu Zhi HUANG ; Wen Bo YANG ; Wen Jiao ZHANG ; Juan ZHOU ; Zu Yi YUAN
Chinese Journal of Cardiology 2023;51(7):722-730
		                        		
		                        			
		                        			Objective: To reveal the similarities and differences in myocardial metabolic characteristics between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) mice using metabolomics. Methods: The experimental mice were divided into 4 groups, including control, HFpEF, sham and HFrEF groups (10 mice in each group). High fat diet and Nω-nitroarginine methyl ester hydrochloride (L-NAME) were applied to construct a"two-hit"HFpEF mouse model. Transverse aortic constriction (TAC) surgery was used to construct the HFrEF mouse model. The differential expression of metabolites in the myocardium of HFpEF and HFrEF mice was detected by untargeted metabolomics (UHPLC-QE-MS). Variable importance in projection>1 and P<0.05 were used as criteria to screen and classify the differentially expressed metabolites between the mice models. KEGG functional enrichment and pathway impact analysis demonstrated significantly altered metabolic pathways in both HFpEF and HFrEF mice. Results: One hundred and nine differentially expressed metabolites were detected in HFpEF mice, and 270 differentially expressed metabolites were detected in HFrEF mice. Compared with the control group, the most significantly changed metabolite in HFpEF mice was glycerophospholipids, while HFrEF mice presented with the largest proportion of carboxylic acids and their derivatives. KEGG enrichment and pathway impact analysis showed that the differentially expressed metabolites in HFpEF mice were mainly enriched in pathways such as biosynthesis of unsaturated fatty acids, ether lipid metabolism, amino sugar and nucleotide sugar metabolism, glycerophospholipid metabolism, arachidonic acid metabolism and arginine and proline metabolism. The differentially expressed metabolites in HFrEF mice were mainly enriched in arginine and proline metabolism, glycine, serine and threonine metabolism, pantothenate and CoA biosynthesis, glycerophospholipid metabolism, nicotinate and nicotinamide metabolism and arachidonic acid metabolism, etc. Conclusions: HFpEF mice have a significantly different myocardial metabolite expression profile compared with HFrEF mice. In addition, biosynthesis of unsaturated fatty acids, arachidonic acid metabolism, glycerophospholipid metabolism and arginine and proline metabolism are significantly altered in both HFpEF and HFrEF mice, suggesting that these metabolic pathways may play an important role in disease progression in both types of heart failure.
		                        		
		                        		
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Heart Failure/metabolism*
		                        			;
		                        		
		                        			Stroke Volume
		                        			;
		                        		
		                        			Chromatography, Liquid
		                        			;
		                        		
		                        			Tandem Mass Spectrometry
		                        			;
		                        		
		                        			Metabolomics
		                        			;
		                        		
		                        			Arachidonic Acids
		                        			;
		                        		
		                        			Proline
		                        			
		                        		
		                        	
4.Discussion on discipline of herbalism.
Ying-Zhan YANG ; Bing LI ; Jia-Lun WANG ; Zi-Ling ZENG ; Wei ZHANG ; Hua-Min ZHANG
China Journal of Chinese Materia Medica 2023;48(23):6519-6525
		                        		
		                        			
		                        			Since the emergence of the term "materia medica", scholars have proposed different opinions on its concept. This term has been used to refer to traditional Chinese medicines, or medical books, or traditional pharmacology. Due to the differences in the concept of materia medica, scholars also have controversies about the concept of herbalism. Herbalism is usually understood as traditional Chinese pharmacology. After years of evolution, the term "herbalism" has now possessed the characteristics of an independent discipline, which can be defined as an applied basic discipline that comprehensively utilizes traditional and modern technological methods to study the formation, development, and changes of traditional pharmacology and reveal the basic theories and application laws of traditional medicine. At present, the research content of herbalism mainly includes three aspects: materia medica history, materia medica literature, and traditional pharmacology. This study explores the disciplinary concepts and main research content of herbalism based on a systematic review of the literature about the concepts of materia medica and herbalism, with the aim of attracting more attention to promote the establishment and development of the discipline of herbalism.
		                        		
		                        		
		                        		
		                        			China
		                        			;
		                        		
		                        			Drugs, Chinese Herbal
		                        			;
		                        		
		                        			Herbal Medicine
		                        			;
		                        		
		                        			Materia Medica
		                        			;
		                        		
		                        			Medicine, Chinese Traditional
		                        			;
		                        		
		                        			Technology
		                        			
		                        		
		                        	
5.The Pathogenic Characteristics of the Initial Three Mpox Cases in Hunan Province, China.
Rong Jiao LIU ; Xing Yu XIANG ; Zi Xiang HE ; Qian Lai SUN ; Fu Qiang LIU ; Shuai Feng ZHOU ; Yi Wei HUANG ; Fang Cai LI ; Chao Yang HUANG ; Juan WANG ; Fang Ling HE ; Xin Hua OU ; Shi Kang LI ; Yu Ying LU ; Fan ZHANG ; Liang CAI ; Hai Ling MA ; Zhi Fei ZHAN
Biomedical and Environmental Sciences 2023;36(12):1167-1170
6.Schisandra chinensis Oil Attenuates Aristolochic Acid I-Induced Nephrotoxicity in vivo and in vitro.
Yan YANG ; Fei-Lin GE ; Xiao-Yan ZHAN ; Wen-Qing MU ; Zhi-Yong LI ; Li LIN ; Zi-Ying WEI ; Zhao-Fang BAI ; Qin SUN ; Xiao-He XIAO
Chinese journal of integrative medicine 2022;28(7):603-611
		                        		
		                        			OBJECTIVE:
		                        			To investigate the protective effects of Schisandra chinensis oil (SCEO) against aristolochic acid I (AA I)-induced nephrotoxicity in vivo and in vitro and elucidate the underlying mechanism.
		                        		
		                        			METHODS:
		                        			C57BL/6 mice were randomly divided into 5 groups according to a random number table, including control group, AA I group, and AA I +SCEO (0.25, 0.5 and 1 g/kg) groups (n=5 per group). Pretreatment with SCEO was done for 2 days by oral administration, while the control and AA I groups were treated with sodium carboxymethyl cellulose. Mice of all groups except for the control group were injected intraperitoneally with AA I (5 mg/kg) from day 3 until day 7. Histopathological examination and apoptosis of kidney tissue were observed by hematoxylin and eosin and TdT-mediated dUTP nick-end labeling (TUNEL) staining, respectively. The levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and serum creatinine (SCr), as well as renal malondialdehyde (MDA), glutathione, r-glutamyl cysteingl+glycine (GSH), and superoxide dismutase (SOD) were analyzed using enzyme-linked immunosorbent assay (ELISA). Expressions of hepatic cytochrome P450 1A1 (CYP1A1), CYP1A2, and nad(p)hquinonedehydrogenase1 (NQO1) were analyzed using ELISA, quantitative real-time polymerase chain reaction (qPCR) and Western blot, respectively. In vitro, SCEO (40 µ g/mL) was added 12 h before treatment with AA I (40 µ mol/mL for 48 h) in human renal proximal tubule cell line (HK-2), then apoptosis and reactive oxygen species (ROS) were analyzed by flow cytometry.
		                        		
		                        			RESULTS:
		                        			SCEO 0.5 and 1 g/kg ameliorated histopathological changes and TUNEL+ staining in the kidney tissues of mice with AA I-induced nephrotoxicity, and reduced serum levels of ALT, AST, BUN and SCr (P<0.01 or P<0.05). SCEO 0.5 and 1 g/kg alleviated the ROS generation in kidney, containing MDA, GSH and SOD (P<0.01 or P<0.05). SCEO 1 g/kg increased the expressions of CYP1A1 and CYP1A2 and decreased NQO1 level in the liver tissues (P<0.01 or P<0.05). Besides, in vitro studies also demonstrated that SCEO 40 µ g/mL inhibited apoptosis and ROS generation (P<0.05 or P<0.01).
		                        		
		                        			CONCLUSIONS
		                        			SCEO can alleviate AA I-induced kidney damage both in vivo and in vitro. The protective mechanism may be closely related to the regulation of metabolic enzymes, thereby inhibiting apoptosis and ROS production.
		                        		
		                        		
		                        		
		                        			Animals
		                        			;
		                        		
		                        			Apoptosis
		                        			;
		                        		
		                        			Aristolochic Acids/toxicity*
		                        			;
		                        		
		                        			Cytochrome P-450 CYP1A1/metabolism*
		                        			;
		                        		
		                        			Cytochrome P-450 CYP1A2/metabolism*
		                        			;
		                        		
		                        			Glutathione/metabolism*
		                        			;
		                        		
		                        			Kidney/drug effects*
		                        			;
		                        		
		                        			Kidney Diseases/drug therapy*
		                        			;
		                        		
		                        			Mice
		                        			;
		                        		
		                        			Mice, Inbred C57BL
		                        			;
		                        		
		                        			Oxidative Stress
		                        			;
		                        		
		                        			Plant Oils/therapeutic use*
		                        			;
		                        		
		                        			Protective Agents/therapeutic use*
		                        			;
		                        		
		                        			Reactive Oxygen Species/metabolism*
		                        			;
		                        		
		                        			Schisandra
		                        			;
		                        		
		                        			Superoxide Dismutase/metabolism*
		                        			
		                        		
		                        	
7.Overview of systematic reviews of acupuncture for vascular cognitive impairment.
Fu-Hua HAN ; Lin-Juan SUN ; Yun-Ling ZHANG ; Zi-Xiu ZENG ; Wei SHEN ; Min ZHAN ; Ying WANG ; Jing-Zi SHI ; Xin-Yun ZENG ; Xi-Yue LU ; Xing LIAO
Chinese Acupuncture & Moxibustion 2022;42(1):109-115
		                        		
		                        			OBJECTIVE:
		                        			To overview the methodological quality, report quality and evidence quality of the systematic review (SR) of acupuncture for vascular cognitive impairment ( VCI ).
		                        		
		                        			METHODS:
		                        			The SRs regarding acupuncture for VCI were searched in PubMed, Cochrane Library, EMbase, CNKI, SinoMed, Wanfang and VIP databases. The retrieval period was from the establishment of the database to September 24, 2020. The report quality, methodological quality and evidence quality of the included SRs were evaluated by PRISMA statement, the AMSTAR 2 tool and the GRADE system.
		                        		
		                        			RESULTS:
		                        			A total of 22 SRs were included, including 102 outcome indexes. The methodological quality was generally low, with low scores on items 2, 5, 7, 10, 14, 15 and 16. The report quality was good, with scores ranging from 19 points to 24.5 points. The problems of report quality were mainly reflected in the aspects of structural abstract, program and registration, other analysis and funding sources. The level of outcome indexes of SRs was mostly low or very low, and the main leading factor was limitation, followed by inconsistency and inaccuracy.
		                        		
		                        			CONCLUSION
		                        			Acupuncture for VCI is supported by low quality evidence of evidence-based medicine, but the methodological quality and evidence body quality of relevant SRs are poor, and the standardization is needed to be improved.
		                        		
		                        		
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Cognitive Dysfunction/therapy*
		                        			;
		                        		
		                        			Databases, Factual
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Research Report
		                        			;
		                        		
		                        			Systematic Reviews as Topic
		                        			
		                        		
		                        	
8.Outcomes in randomized controlled trials of acupuncture for vascular cognitive impairment during recent five years.
Xin-Yun ZENG ; Xing LIAO ; Yun-Ling ZHANG ; Zi-Xiu ZENG ; Wei SHEN ; Min ZHAN ; Ying WANG ; Fu-Hua HAN ; Jing-Zi SHI ; Xi-Yue LU
Chinese Acupuncture & Moxibustion 2022;42(5):590-594
		                        		
		                        			
		                        			The existing problems in the outcomes of randomized controlled trials (RCTs) of acupuncture for vascular cognitive impairment (VCI) during recent five years are analyzed and suggestions are proposed. The RCTs of acupuncture for VCI were selected in PubMed, EMbase, Cochrane Library, Clinical Trials, CNKI database, Wanfang database, VIP database, SinoMed database and Chinese Clinical Trial Registry (ChiCTR) from January 1, 2015 to September 14, 2020. The outcomes were extracted and analyzed. As a result, 21 RCTs were included and the outcomes used were divided into 9 categories: clinical symptom/sign indexes, quality of life indexes, neuroimaging indexes, neuroelectrophysiology indexes, blood biochemical indexes, hemorheology indexes, TCM syndrome score indexes, clinical efficacy indexes, and safety indexes. Among them, the top three of the most used outcomes were clinical symptoms/signs indexes (21, 100.0%), clinical efficacy indexes (14, 66.7%) and quality of life indexes (12, 57.1%). In the RCTs of acupuncture for VCI, attention should be paid to distinguish the primary outcomes and secondary outcomes, adopt objective and standardized efficacy evaluation, and give consideration to report the outcomes of safety, health economic and TCM characteristic indexes.
		                        		
		                        		
		                        		
		                        			Acupuncture Therapy
		                        			;
		                        		
		                        			Cognitive Dysfunction/therapy*
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Randomized Controlled Trials as Topic
		                        			;
		                        		
		                        			Treatment Outcome
		                        			
		                        		
		                        	
10.Research advance in multi-component pharmacokinetics of Chinese herbal extracts in recent five years.
Lu-Jing CAO ; Shu-Yu ZHAN ; Xiang-Yu JI ; Bo-Hong ZHENG ; Chun-Ying YE ; Zi-Yi CHEN ; Guo-Qiang LIU ; Bao-Yue DING
China Journal of Chinese Materia Medica 2021;46(13):3270-3287
		                        		
		                        			
		                        			The multi-component pharmacokinetic study of Chinese herbal extracts elaborates the in vivo processes,including absorption,distribution,metabolism,and excretion,of multiple bioactive components,which is of significance in revealing pharmacodynamic material basis of Chinese herbal medicine. In recent years,with the innovation in ideas,and development of techniques and methods on traditional Chinese medicine( TCM) research,the pharmacokinetic studies of Chinese herbal extracts were extensively performed,and notable progress has been made. This paper reviewed the advancement of multi-component pharmacokinetics of Chinese herbal extracts in recent five years from analysis technology of biological sample,the pharmacokinetic characteristics of Chinese herbal medicine with complex system,and the impacts of processing and pathological state on pharmacokinetics of Chinese herbal extracts,aiming to provide a reference for quality control,product development and rational medication of Chinese herbal extracts.
		                        		
		                        		
		                        		
		                        			China
		                        			;
		                        		
		                        			Drugs, Chinese Herbal
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Medicine, Chinese Traditional
		                        			;
		                        		
		                        			Quality Control
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail